SOURCE: Greenleaf Medical
LOS ANGELES, CA--(Marketwire - Mar 7, 2013) - Greenleaf Medical was awarded the Best New Ingredient NutrAward for its appetite suppressant ingredient Appethyl™. The 15th annual 2013 NutrAwards were held in Anaheim, California on Wednesday, March 6, 2013 from 5:00PM-7:00PM. Runners-up for Best New Ingredient included Lcr35 3Biotic Formulation by Probionov and Meratrim® by InterHealth Nutraceuticals.
The criteria for the Best New Ingredient included scientific merit, efficacy, market potential, safety, innovation, ability to increase market credibility, introduced from January 2010 to present. Greenleaf Medical AB was selected based on a weighted vote from the selection committee (consisting of a panel of industry experts, scientists and nutritionists), as well as by cumulative votes of attendees registered for Nutracon, Engredea and Natural Products Expo West.
"Winning the Best New Ingredient for Appethyl™ was complete validation for the commitment we've made in Research and Development. The science and innovation was paramount for the creation of an evidence-based health and nutrition ingredient," said Anders Struksnes, Chief Executive Officer of Greenleaf Medical AB. "We are excited that we were chosen by our peers as well as the esteemed members of the NutrAwards selection committee."
The NutrAward program was created to reward and recognize companies investing in rigorous and measurable scientific studies to prove the efficacy of their proprietary ingredients, products, or technologies.
The beneficial attributes of Appethyl™, which Greenleaf Medical AB has protected via three pending patents, have been validated by preclinical and clinical studies at Sweden's Lund University. Professors C. Erlanson-Albertsson and P-Å. Albertsson are the principal investigators in this work and a doctoral thesis, Thylakoid Membranes and pancreatic lipase/colipase; Thylakoid membranes retard digestion of fat and suppress appetite, has been presented on the subject.
Appethyl™ is an all-natural spinach extract standardized to thylakoids that can be formulated into food and drinks. Its primary effect is to significantly reduce hunger while also having two very interesting secondary effects. These secondary effects include reduction of postprandial blood insulin levels as well as functioning as a prebiotic (i.e. increasing the growth of beneficial bacteria). This mechanism by which Appethyl™ reduces appetite significantly is by delaying the activity of pancreatic lipase/colipase, which in turn increases levels of Cholecystokinin, the body's primary satiety hormone.
"We know this industry recognition will help provide additional industry awareness and validation for Appethyl™ and its many uses in various delivery systems. The claims behind Appethyl™ have been substantiated clinically and since its primary effect is to significantly reduce appetite, this new ingredient is an excellent new addition to the weight loss category. Appetite suppression is currently considered one of the biggest product opportunities in the weight loss sector," said Dan Edwall, Chairman of the Board and VP of Research and Development for Greenleaf Medical AB.
For more information on Appethyl™ or Greenleaf Medical AB, please visit http://www.gl-medical.com or contact Maria Söderberg at +46 70 869 27 06, (GMT+1) email: ms(at)gl-medical(dot)com. To learn more about the NutrAwards, visit http://www.nutraward.com.
Nutracon is the premier conference for ingredient and technology innovation within the health and nutrition industry. The conference provides relevant insights for innovation based on science and technology, case studies and market intelligence. Attendees gain an understanding of the impact of "next generation" ingredients, emerging markets, consumer trend data and regulatory constraints.
Cutting-edge conference tracks are prepared and presented in collaboration with world-class researchers and carefully selected partners (industry, academic, and government) to ensure top-notch science, solid business and industry context, and the highest potential for commercial or health-policy impact.
About Greenleaf Medical AB
Greenleaf Medical is a Swedish research and development company, active in the global nutraceutical market, which sells and develops natural ingredients with well-documented, beneficial health effects. We work together with universities and international science and regulatory groups. Our products are used in both Functional Food and Dietary Supplements.
Greenleaf Medical believes the secret of health and beauty is based on finding the best ingredient through scientific validation. Dedicated to creating natural products with published mechanism-of-action and efficacy studies, the Greenleaf Medical team believes in the unique composition of natural, active ingredients and innovative formula of their supplements.